Handajani R, Lusida M I, Darmadi S, Adi P, Ishido S, Katayama Y, Hotta H
Tropical Disease Research Center, Airlangga University, Surabaya, Indonesia.
J Clin Microbiol. 1996 Dec;34(12):2875-80. doi: 10.1128/jcm.34.12.2875-2880.1996.
Determination of the prevalence of liver disease caused by hepatitis C virus (HCV) of various genotypes helps provide an understanding of the virulences of these genotypes. Differences in the prevalences of these genotypes are known to exist in the various geographical regions of the world. Hence, we performed seroepidemiological and molecular epidemiological analyses of HCV in Surabaya, Indonesia. The prevalences of anti-HCV antibodies were 2.3, 76.3 and 64.7% in healthy blood donors, patients on maintenance hemodialysis, and patients with hepatocellular carcinoma (HCC), respectively. HCV-2a was the most common (52%) among the HCV clones obtained from blood donors; this was followed by HCV-1b (15%), HCV-1a (7%), and HCV-1d (7%), a unique Indonesian subtype. The high prevalence of HCV-2a in blood donors was further supported by serotyping analysis that could discriminate HCV type 2 (HCV-2a and -2b) from HCV type 1 (HCV-1a, -1b, and -1d). HCV-1a, -1b, and -1d were strongly associated with elevated serum alanine aminotransferase (ALT) levels in blood donors, suggesting a possibly more pathogenic feature of those subtypes than HCV-2a. In patients on maintenance hemodialysis, HCV-1a and -1b (each 31%) were among the most common subtypes, and in contrast to the case with blood donors, HCV-1a, -1b, and -1d were found in those with normal ALT as well as those with elevated ALT levels. Impaired immune responses of hemodialyzed patients might be responsible for the apparently decreased hepatocytic injury caused by infection with HCV type 1. In patients with HCC, HCV-1b (57%) was the most common; this was followed by HCV-1d (19%) and HCV-2a (5%). Subtype prevalence was not different between HCC patients with advanced liver cirrhosis and those without advanced cirrhosis.
确定由丙型肝炎病毒(HCV)不同基因型引起的肝病患病率,有助于了解这些基因型的毒力。已知这些基因型的患病率在世界不同地理区域存在差异。因此,我们在印度尼西亚泗水对HCV进行了血清流行病学和分子流行病学分析。健康献血者、维持性血液透析患者和肝细胞癌(HCC)患者中抗-HCV抗体的患病率分别为2.3%、76.3%和64.7%。在从献血者获得的HCV克隆中,HCV-2a最为常见(52%);其次是HCV-1b(15%)、HCV-1a(7%)和HCV-1d(7%),后者是一种独特的印度尼西亚亚型。血清分型分析进一步支持了献血者中HCV-2a的高患病率,该分析能够区分HCV 2型(HCV-2a和-2b)与HCV 1型(HCV- la、-1b和-1d)。HCV-1a、-1b和-1d与献血者血清丙氨酸氨基转移酶(ALT)水平升高密切相关,表明这些亚型可能比HCV-2a具有更强的致病特征。在维持性血液透析患者中,HCV-1a和-1b(各占31%)是最常见的亚型之一,与献血者不同的是,在ALT正常和ALT水平升高的患者中均发现了HCV-1a、-1b和-1d。血液透析患者免疫反应受损可能是1型HCV感染导致肝细胞损伤明显减少的原因。在HCC患者中,HCV-1b(57%)最为常见;其次是HCV-1d(19%)和HCV-2a(5%)。晚期肝硬化的HCC患者和无晚期肝硬化的HCC患者之间的亚型患病率没有差异。